Sepracor "outperform"

03/08/07 - Credit Suisse

NEW YORK, March 8 (newratings.com) - Analyst M Goodman of Credit Suisse maintains his "outperform" rating on Sepracor Inc (SEPR). The target price is set to $65.

In a research note published yesterday, the analyst mentions that the company is expected to receive double-digit royalties going forward, if the Levocertirizine drug, which is partnered with Sanofi, receives full FDA approval. Credit Suisse expects the company's share price to appreciate significantly during the year. The alteration in the CMS reimbursement for Xopenex is likely to either have a marginal adverse impact or no impact at all on the company’s performance going forward, Credit Suisse adds.